Home › Funds › Catalio Capital Management, LP › DYN

Catalio Capital Management, LP position in DYN

DYNE THERAPEUTICS INC · Health Care

Catalio Capital Management, LP reported holding 244,929 shares of DYN (DYNE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$5.4M, representing 1.02% of its reported portfolio and ranking #29 among its reported holdings. Catalio Capital Management, LP has disclosed DYN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)244.93K sh
Reported value held$5.44M
Portfolio Weight1.02%
First reportedQ4 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Catalio Capital Management, LP's DYN position evolved

Catalio Capital Management, LP first disclosed a stake in DYN in Q4 2025 at 519,715 shares (US$10.2M). Across 3 filings, Catalio Capital Management, LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 244,929 shares valued at US$5.4M — a reduction of -38,025 shares quarter over quarter.. Notable position changes include a 46% trim in Q1 2026 (shares rose 23% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 519.72K $10.17M New
Q1 2026 282.95K $5.13M Reduce
Q2 2026 244.93K $5.44M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DYN and 13F data

DYN (DYNE THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in DYN — the largest reported positions include Atlas Venture Life Science Advisors, LLC (US$151.0M), TCG Crossover Management, LLC (US$102.5M), FCPM III SERVICES B.V. (US$85.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DYN

All DYN fund holders →

FAQ

How long has Catalio Capital Management, LP held DYN?

Catalio Capital Management, LP has disclosed DYN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Catalio Capital Management, LP's current position in DYN?

As of Q2 2026, Catalio Capital Management, LP holds 244.93K shares of DYN (DYNE THERAPEUTICS INC), valued at $5.44M, representing 1.02% of its reported portfolio and ranking #29.

Has Catalio Capital Management, LP been buying or selling DYN?

In the latest 13F filing (Q2 2026), Catalio Capital Management, LP reduced its position in DYN.

Which other funds hold DYN?

Other major institutional holders of DYN include Atlas Venture Life Science Advisors, LLC, TCG Crossover Management, LLC, FCPM III SERVICES B.V., among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.